UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 20, 2005
(Exact name of registrant as specified in its charter)
|
MASSACHUSETTS |
000-19319 |
04-3039129 |
130 Waverly Street
Cambridge, Massachusetts 02139
(Address of principal executive offices) (Zip Code)
(617) 444-6100
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
On May 10, 2005, Vertex Pharmaceuticals Incorporated (the “Company”) issued a press release that announced interim results indicating that the Company’s investigational oral hepatitis C virus (“HCV”) protease inhibitor, VX-950, was well-tolerated and demonstrated potent antiviral activity in a Phase Ib clinical trial. A copy of that press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
On May 17, 2005, the Company issued a press release that described the results of the Phase Ib clinical trial in further detail. A copy of that press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits
|
Exhibit |
|
Description of Document |
|
|
|
|
|
99.1 |
|
Press Release of Vertex Pharmaceuticals Incorporated, dated May 10, 2005, titled “Vertex Pharmaceuticals Reports that VX-950, an Investigational Oral Hepatitis C Protease Inhibitor, Displays Potent Antiviral Activity in Early Clinical Study”. |
|
|
|
|
|
99.2 |
|
Press Release of Vertex Pharmaceuticals Incorporated, dated May 17, 2005, titled “Vertex Pharmaceuticals Reports that Oral Hepatitis C Protease Inhibitor, VX-950, Dramatically Reduces Viral Levels in Phase Ib Clinical Study”. |
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
VERTEX PHARMACEUTICALS INCORPORATED |
|
|
|
|
|
|
|
Date: May 20, 2005 |
/s/ Kenneth S. Boger |
|
|
Kenneth S. Boger |
2